Weakened in R&D investments of listed pharmaceutical companies

Published: 2014-12-03 13:46:12

Updated: 2014-12-03 13:46:12

It is known that listed pharmaceutical companieshave taken a step backon investments in research and development (R&D).

According to the YakupDotCom’s (www.yakup.com) analysis result of the 55 listed pharmaceutical companies’quarterly sales reports on the third quarter in 2014, R&D investments of the companiesaccounted for 7.7% of their total sales.

Compared to the result in 2013, it raised a...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.